ASH Announces Kenneth Anderson as New President
Multiple myeloma expert Kenneth C. Anderson, MD, will serve as president of the American Society of Hematology through the end of this year.
Kenneth C. Anderson, MD
Kenneth C. Anderson, MD
Multiple myeloma expert Kenneth C. Anderson, MD, will serve as president of the American Society of Hematology (ASH) through the end of this year, ASH has announced.
Anderson is director of the Lebow Institute for Myeloma Therapeutics and the Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. He also serves as Kraft Family Professor of Medicine and vice chair of the Joint Program in Transfusion Medicine at Harvard Medical School in Cambridge.
“In this time of unprecedented scientific discovery, especially in hematology, ASH has an important role in supporting high-impact and cross-cutting research, quality in medical practice, and access to hematologic care,” Anderson said. “As ASH president, I look forward to continuing the Society’s commitment to training, education, research, and advocacy to accelerate the development of today’s scientific advances so they can benefit patients with blood diseases all over the world.”
Anderson has served in a variety of volunteer roles with ASH for more than 30 years, including as executive director of ASH’s education program, Hematology, an ASH councilor, and as co-chair of the inaugural ASH Meeting on Hematologic Malignancies.
As ASH president-elect in 2016, Anderson served as the Society’s representative to the National Cancer Moonshot effort, and he continues to lead efforts towards developing a system for sharing multiple myeloma and ultimately other hematologic cancer data between the world’s top research centers, according to a news release from ASH.
As ASH’s new president, Anderson plans to identify new opportunities to attract and groom the next generation of hematologists through mentorship opportunities with experts in the field. He also seeks to continue the Society’s strong record of advocating for sound investment in cutting-edge science, including precision medicine and immunologic therapies, as well as exploring new avenues for increasing quality and access to care around the world, according to the release.
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
